Fluidigm (FLDM) Posts Earnings Results, Beats Estimates By $0.07 EPS

Share on StockTwits

Fluidigm (NASDAQ:FLDM) posted its earnings results on Thursday. The medical research company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07, Morningstar.com reports. The firm had revenue of $32.33 million during the quarter, compared to analysts’ expectations of $30.55 million. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 90.07%.

NASDAQ FLDM traded up $0.80 during trading hours on Friday, reaching $9.35. The company’s stock had a trading volume of 3,626,242 shares, compared to its average volume of 635,439. The firm has a market cap of $367.64 million, a PE ratio of -11.69 and a beta of 2.29. Fluidigm has a 52 week low of $4.65 and a 52 week high of $9.76. The company has a debt-to-equity ratio of 7.56, a current ratio of 1.85 and a quick ratio of 1.45.

In other Fluidigm news, insider Levin Capital Strategies, L.P. acquired 35,033 shares of the company’s stock in a transaction that occurred on Monday, December 10th. The stock was acquired at an average price of $7.72 per share, for a total transaction of $270,454.76. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders purchased 1,083,700 shares of company stock valued at $7,387,908. 2.20% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Quantamental Technologies LLC bought a new position in Fluidigm in the 4th quarter valued at approximately $61,000. Rhumbline Advisers increased its position in Fluidigm by 42.9% during the 4th quarter. Rhumbline Advisers now owns 34,489 shares of the medical research company’s stock valued at $297,000 after purchasing an additional 10,358 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in Fluidigm during the 3rd quarter valued at approximately $117,000. Neuberger Berman Group LLC increased its position in Fluidigm by 0.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 4,535,180 shares of the medical research company’s stock valued at $33,971,000 after purchasing an additional 24,186 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Fluidigm by 8.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 433,511 shares of the medical research company’s stock valued at $2,585,000 after purchasing an additional 35,091 shares during the period. Institutional investors and hedge funds own 98.30% of the company’s stock.

FLDM has been the subject of a number of research reports. Zacks Investment Research cut shares of Fluidigm from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. ValuEngine raised shares of Fluidigm from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. BidaskClub raised shares of Fluidigm from a “hold” rating to a “buy” rating in a report on Thursday, December 27th. Janney Montgomery Scott raised shares of Fluidigm from a “neutral” rating to a “buy” rating in a report on Thursday, January 3rd. Finally, Piper Jaffray Companies raised shares of Fluidigm from a “neutral” rating to an “overweight” rating in a report on Friday, November 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $9.25.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Macon Daily and is owned by of Macon Daily. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://macondaily.com/2019/02/09/fluidigm-fldm-posts-earnings-results-beats-estimates-by-0-07-eps.html.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Recommended Story: Liquidity

Earnings History for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply